RVL Pharmaceuticals Stock (NASDAQ:RVLP)
Previous Close
$0.04
52W Range
- - $1.66
50D Avg
$0.09
200D Avg
$0.66
Market Cap
$3.14M
Avg Vol (3M)
$24.42M
Beta
1.09
Div Yield
-
RVLP Company Profile
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
RVLP Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CYT | Cyteir Therapeutics, Inc. |
| NUVB | Nuvation Bio Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| NXTC | NextCure, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| SNSE | Sensei Biotherapeutics, Inc. |
| CSBR | Champions Oncology, Inc. |
| GRPH | LENZ Therapeutics, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| HCWB | HCW Biologics Inc. |
| MNOV | MediciNova, Inc. |
| RZLT | Rezolute, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| MOLN | Molecular Partners AG |
| MACK | Merrimack Pharmaceuticals, Inc. |
| ELYM | Eliem Therapeutics, Inc. |